Subject(s)
Anxiety/etiology , Lung Neoplasms/diagnosis , Paraneoplastic Syndromes, Nervous System/diagnosis , Small Cell Lung Carcinoma/diagnosis , Thinness/diagnosis , Weight Loss/physiology , Carcinoma, Neuroendocrine/complications , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/pathology , Delayed Diagnosis , Gastroparesis/diagnosis , Gastroparesis/etiology , Humans , Lung Neoplasms/complications , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Metastasis , Paraneoplastic Syndromes, Nervous System/complications , Small Cell Lung Carcinoma/complications , Small Cell Lung Carcinoma/pathology , Thinness/etiology , Time FactorsABSTRACT
Experimental and theoretical physico-chemical methods were used to investigate the interaction between aryl-oxazolidinones and monoamine oxidase (MAO). Several arguments suggest that these compounds interact with the flavin adenine dinucleotide (FAD) cofactor of MAO. The calculation using ab initio molecular orbital methods of the electronic properties of flavin and befloxatone, a reversible inhibitor of MAO A, led to a description of the interaction between aryl-oxazolidinones and the cofactor of the enzyme. Structure activity relationship results revealed additional sites of interaction with the protein core of MAO A. As a result of this work, a model is proposed for the reversible inhibition of MAO by oxazolidinones via long distance, reversible interactions with the FAD cofactor of the enzyme.